Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.55 |
| ▸ | TUBB | P07437 | 2/20 | 0.55 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.55 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.55 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.55 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.55 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.55 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.55 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.55 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.55 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.55 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.55 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.55 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3566445 | 0.98 | PDE4D (0.57) | PDE4DCA1CA2TUBB4ATUBB | |
| SCHEMBL2664428 | 0.86 | MEN1 (0.66) | CA1CA2ALDH1A1CYP1A2MEN1 | |
| SCHEMBL29412632 | 0.86 | CYP1A2 (0.63) | CA1CA2ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL2446906 | 0.86 | CYP1A2 (0.63) | CA1CA2ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL19519009 | 0.84 | PDE4D (0.60) | PDE4DTUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6511902 | 0.84 | HDAC6 (0.61) | PDE4DCA1CA2TUBB4ATUBB | |
| SCHEMBL6511696 | 0.83 | TAS1R3 (0.65) | CA1CA2ALDH1A1CYP3A4CYP1A2 | |
| SCHEMBL11328691 | 0.83 | ALDH1A1 (0.69) | PDE4DCA1CA2TUBB4ATUBB | |
| SCHEMBL30622701 | 0.81 | HTT (0.65) | PDE4DCA1CA2ALDH1A1CYP3A4 | |
| SCHEMBL6580514 | 0.81 | ALDH1A1 (0.63) | CA1CA2ALDH1A1CYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209573-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-20 | — | — | US | claimed |
| EP-1804803-A4 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-07-30 | — | — | EP | claimed |
| EP-1804803-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2007-07-11 | — | — | EP | claimed |
| WO-2006050351-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2006-05-11 | — | — | WO | claimed |
| EP-2594555-B1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA PHARM CO LTD (JP) | 2018-03-07 | — | — | EP | disclosed |
| US-9200008-B2 | Heterocyclic compound and p27Kip1 degradation inhibitor | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-01 | — | — | US | disclosed |
| EP-2594555-A1 | HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR | ASKA Pharmaceutical Co., Ltd. (JP) | 2013-05-22 | — | — | EP | disclosed |
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-28 | — | — | US | disclosed |
| US-20090209573-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-20 | — | — | US | disclosed |
| EP-1804803-A4 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-07-30 | — | — | EP | disclosed |
| EP-1804803-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM, LLC (BM) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006050351-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079306-A1 | HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR | CDKN1A, SKP2, CCNI | PDE4D 4059/4885CA1 1503/4885CA2 790/4885 |
| US-20090209573-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | PDE4D 2907/4885CA1 1644/4885CA2 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.